PharmaFocus Today – Page 31 – media

Luoxin Pharmaceutical plans to raise no more than 842 million yuan for innovative drug research and development! Losing 2.8 billion yuan in three years, causing a sharp drop in monetary funds

On the evening of September 29th, Luoxin Pharmaceutical (002793) announced that it plans to raise no more than 842 million yuan for innovative drug research and development projects, raw material drug expansion and freeze-drying workshop technology renovation projects, and to supplement working capital. According to the data, Luoxin Pharmaceutical is mainly engaged in the research, development, production and sales of pharmaceutical products, focusing on digestion, respiration, anti-tumor and other advantageous fields. Its products are mainly chemical preparations, chemical raw materials, and traditional Chinese patent medicines and simple preparations. The company was listed on the Shenzhen Stock Exchange in April 2016. Luoxin Pharmaceutical stated that in order to strengthen the company’s innovative drug product layout and improve the market competitiveness of innovative drug products, the innovative drug research and development project in this fundraising investment project will focus on the Phase II and III clinical studies of LX22001 for injection to ...
- Source: drugdu
- 137
- October 2, 2025
Changchun High tech goes public in Hong Kong, ‘Hormone Grass’ accelerates search for breakthrough path

Changchun High tech, which once dominated the capital market with growth hormone, is accelerating its plan to go public in Hong Kong after experiencing a performance slump, attempting to find a new way out in the midst of difficulties. On September 29th, according to the Hong Kong Stock Exchange, Changchun High Tech Industry (Group) Co., Ltd. (referred to as “Changchun High Tech”) from Changchun, Jilin submitted a prospectus to the Hong Kong Stock Exchange, intending to be listed on the main board of Hong Kong. Changchun High Tech was listed on the Shenzhen Stock Exchange on December 18, 1996, and as of the close of trading on September 29, 2025, its total market value was RMB 52.583 billion. This marks the official launch of the “A+H” dual platform listing journey for the growth hormone Mao, which once created a “myth” in the A-share market. A pharmaceutical industry analyst from a ...
- Source: drugdu
- 342
- October 2, 2025
Researchers design factor IX variants for short- and long-term Hemophilia B management

After blood vessel damage, effective blood clotting is essential to halt bleeding. However, this process is inefficient in some individuals due to hereditary factors. Hemophilia B, for example, results from a deficiency in coagulation factor IX (FIX), which can lead to prolonged bleeding after injuries or surgery. Thus, patients with hemophilia B are often treated with recombinant FIX as a replacement therapy, and while this approach has improved treatment for hemophilia B, the plasma half-lives of the approved products are only about 3-4 days, and frequent injections are needed. Consequently, there is a pressing need for recombinant FIX products with enhanced plasma half-life that allows less frequent dosing. In the current study, the laboratories of Professor Jan Terje Andersen at the University of Oslo and Alessio Branchini/Mirko Pinotti at the University of Ferrara (Italy) present design and characterization of long-acting human albumin-fused FIX variants, each exhibiting unique pharmacokinetic properties. The ...
- Source: drugdu
- 94
- September 30, 2025
FDA Approves Opzelura for Atopic Dermatitis in Children

By Lori Solomon HealthDay ReporterMONDAY, Sept. 29, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Opzelura cream 1.5 percent (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD). The approval is the first topical Janus kinase (JAK) inhibitor for the short-term, noncontinuous chronic treatment of mild-to-moderate AD in nonimmunocompromised children (age 2 years and older) whose disease is not well controlled with topical prescription therapies or when topical therapies are not recommended. The approval is based on results from the phase 3 TRuE-AD3 trial, which evaluated the safety and efficacy of Opzelura cream in children ages 2 to <12 years with AD. The primary end point was met, with significantly more patients treated with Opzelura achieving Investigator’s Global Assessment-treatment success versus patients treated with vehicle control cream. The trial also met the secondary end point of more Opzelura-treated patients demonstrating ≥75 percent improvement ...
- Source: drugdu
- 130
- September 30, 2025
Lunan Pharmaceutical’s blockbuster first generic drug approved, ushering in changes in the allergy market

Recently, the official website of the State Food and Drug Administration announced that the orally disintegrating tablets of Bilastine, which were submitted by Shandong Xinshidai Pharmaceutical, a subsidiary of Lunan Pharmaceutical Group, under the Class 3 chemical drug registration classification, have been approved for marketing and are deemed to have passed the generic drug quality and efficacy consistency evaluation. They are used for the symptomatic treatment of urticaria in adults and adolescents (12 years and above). The original product, Bilastine, was developed by FAES Pharmaceuticals of Spain and first marketed in the EU in August 2010. In June 2023, Menarini’s Bilastine tablets were approved for marketing in China. In 2024, Jiangsu Huayang Pharmaceutical secured the first domestic generic version of Bilastine tablets. This time, Lunan Pharmaceutical’s Bilastine orally disintegrating tablets were approved for marketing, marking the first domestic generic version of this dosage form and the first to pass review. ...
- Source: drugdu
- 114
- September 30, 2025
A subsidiary received approval for clinical trials of HRS-2129 tablets. Currently, no drug with the same target has been approved for marketing in China.

According to the AI news of the China Business Network, on September 29, Hengrui Medicine (600276.SH) announced that its subsidiaries Shandong Shengdi Pharmaceutical Co., Ltd. and Shanghai Hengrui Medicine Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration for HRS-2129 tablets, agreeing to conduct clinical trials for the indications of adult diabetic peripheral neuropathy pain and adult osteoarthritis pain. HRS-2129 tablets are intended for the treatment of acute and chronic pain. Currently, no drugs with the same target have been approved for marketing in China. As of now, the cumulative R&D investment in this project is approximately 112 million yuan. According to relevant laws and regulations, after obtaining the drug clinical trial approval notice, the drug must still conduct clinical trials and be reviewed and approved by the National Medical Products Administration before it can be produced and marketed. https://finance.eastmoney.com/a/202509293526362066.html
- Source: drugdu
- 166
- September 30, 2025
Eli Lilly’s new drug Inluriyo has been approved by the US FDA for the treatment of advanced or metastatic breast cancer

Recently, Eli Lillyannounced that the U.S. Food and Drug Administration (FDA) has approved its oral estrogen receptor antagonist Inluriyo (imlunestrant, 200 mg tablets) for the treatment of adult patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease has progressed after at least one line of endocrine therapy (ET). https://finance.eastmoney.com/a/202509283525492454.html
- Source: drugdu
- 111
- September 29, 2025
New specifications of sitagliptin and metformin extended-release tablets approved

　　Xuantai PharmaceuticalOn September 26, the company announced that its wholly-owned subsidiary, Jiangsu Xuantai Pharmaceutical Co., Ltd., received the “Notice of Approval of Supplementary Drug Application” from the National Medical Products Administration (NMPA). The NMPA approved the company’s supplemental application for sitagliptin and metformin extended-release tablets to include 50 mg of sitagliptin phosphate (calculated as CHFNO3) and 500 mg of metformin hydrochloride per tablet. Currently marketed, the dosage form contains 50 mg of sitagliptin phosphate (calculated as CHFNO3) and 1000 mg of metformin hydrochloride per tablet. This newly approved dosage form will help better meet patient needs, enhance product competitiveness and market share, and positively impact the company’s future performance. https://finance.eastmoney.com/a/202509263524765181.html
- Source: drugdu
- 89
- September 29, 2025
Based on the logic of prosperity and industry trends, public fundraising explores advantages, styles, and opportunities for “diffusion”

Since the Federal Reserve cut interest rates in September, the technology growth style of the A-share market has continued to strengthen. As of September 26th, several semiconductor equipment related themed ETFs have performed well. Industry institutions analyze that new developments in the artificial intelligence (AI) industry are constantly emerging, and the structural market driven by growth styles is still ongoing. However, with the “pre holiday effect” of the National Day holiday, if there is no significant positive catalyst, the market may be mainly volatile in the near future. At the same time as the valuation of the technology sector enters a high level, the internal rotation of the sector is also accelerating. Industry institutions suggest that the previous extreme structural differentiation and overly concentrated consensus in the market need to be digested and consolidated. In the current market driven by incremental funds and the prosperity of some industries, rotation is ...
- Source: drugdu
- 101
- September 29, 2025
Guangzhou Pharmaceutical Baiyunshan’s fund plans to invest 749 million yuan to become the second largest shareholder of Nanjing Pharmaceutical

On the evening of September 28th, Baiyunshan, a listed company under Guangzhou Pharmaceutical Group, and Nanjing Pharmaceutical Co., Ltd. (hereinafter referred to as “Nanjing Pharmaceutical”) announced that Baiyunshan’s Guangzhou Pharmaceutical Phase II Fund Equity Investment Partnership Enterprise (Limited Partnership) (hereinafter referred to as “Guangzhou Pharmaceutical Phase II Fund”) plans to invest 749 million yuan to acquire 145 million non restricted shares of Nanjing Pharmaceutical held by Alliance Healthcare Asia Pacific Limited (“AHAPL”), accounting for 11.04% of the total shares of Nanjing Pharmaceutical. After the acquisition is completed, Guangzhou Pharmaceutical Phase II Fund will become the second largest shareholder of Nanjing Pharmaceutical. According to the announcement, on September 26th, Guangzhou Pharmaceutical Phase II Fund signed a share transfer contract with AHAPL. The buyer and seller agreed to use the arithmetic mean of the daily closing prices of the target company for the 60 trading days prior to the signing date ...
- Source: drugdu
- 138
- September 29, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.